Akinlade, B., Guttman-Yassky, E., de Bruin-Weller, M. et al. (25 more authors) (2019) Conjunctivitis in dupilumab clinical trials. British Journal of Dermatology, 181 (3). pp. 459-473. ISSN 0007-0963
Abstract
BACKGROUND: Dupilumab, which blocks the shared receptor component for interleukin (IL)-4 and IL-13, is approved for inadequately-controlled moderate-to-severe atopic dermatitis (AD) and moderate-to-severe eosinophilic or oral corticosteroid-dependent asthma. AD trials reported increased conjunctivitis incidence for dupilumab vs. placebo. OBJECTIVES: To further characterise conjunctivitis occurrence and risk factors in dupilumab clinical trials. Methods We evaluated randomised placebo-controlled trials of dupilumab in AD (n=2629), asthma (n=2876), chronic rhinosinusitis with nasal polyps (CRSwNP) (n=60), and eosinophilic esophagitis (EoE) (n=47). RESULTS: In most AD trials, dupilumab-treated patients had higher conjunctivitis incidence than placebo controls. Higher baseline AD severity and previous conjunctivitis history were associated with increased conjunctivitis incidence. Conjunctivitis was mostly mild to moderate. Most cases recovered/resolved during the treatment period; 2 patients permanently discontinued dupilumab due to conjunctivitis/keratitis. Common treatments included ophthalmic corticosteroids, antibiotics, and anti-histamines/mast cell stabilisers. Most cases were diagnosed by investigators. In asthma and CRSwNP trials, conjunctivitis incidence was lower for both dupilumab and placebo than in AD trials; dupilumab did not increase incidence vs. placebo. In the EoE trial, no patients had conjunctivitis. CONCLUSIONS: Conjunctivitis was more frequent with dupilumab treatment in most AD trials. In dupilumab trials in other type 2 diseases, incidence of conjunctivitis was overall very low, and was similar for dupilumab and placebo. In AD, conjunctivitis incidence was associated with AD severity and prior history of conjunctivitis. The aetiology and treatment of conjunctivitis in dupilumab-treated patients require further study.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © 2019 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, (http://creativecommons.org/licenses/by-nc-nd/4.0/) which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
Keywords: | Dupilumab; asthma; atopic dermatitis; conjunctivitis; nasal polyps |
Dates: |
|
Institution: | The University of Sheffield |
Academic Units: | The University of Sheffield > Sheffield Teaching Hospitals |
Depositing User: | Symplectic Sheffield |
Date Deposited: | 08 May 2019 14:13 |
Last Modified: | 02 Dec 2021 10:58 |
Status: | Published |
Publisher: | Wiley |
Refereed: | Yes |
Identification Number: | 10.1111/bjd.17869 |
Related URLs: | |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:145742 |
Download
Filename: Akinlade_et_al-2019-British_Journal_of_Dermatology.pdf
Licence: CC-BY-NC-ND 4.0